Therapeutic target identification and drug-target validation for acute myeloid leukemia

van Gils, N

Publication date

November 2022

Publisher

Off Page

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy characterized by accumulation of immature myeloid cells with aberrant proliferation, differentiation and survival capacity in the patient’s bone marrow (BM) and peripheral blood. Most AML patients are treated with standard combination chemotherapy consisting of cytarabine and an anthracycline, aiming at achieving complete remission (CR, <5% leukemic blasts). Although most AML patients achieve CR after initial treatment, the overall survival is less than 40%. The major cause of treatment failure in AML is intrinsic heterogeneity in treatment response. After therapy, a small population of leukemic cells survives (minimal or measurable residual disease, MRD) and has the capacity to dev...

Extracted data

We use cookies to provide a better user experience.

Data Protection

Therapeutic target identification and drug-target validation for acute myeloid leukemia

Abstract

Extracted data

Therapeutic target identification and drug-target validation for acute myeloid leukemia

Abstract

Extracted data

Related items

Related items